Clinical trials: Spondyloarthritis, Axial
Ankylosing Spondylitis
Safety and Tolerance of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Ankylosing Spondylitis
The goal of this clinical trial is to evaluate the safety and tolerability of multiple doses of human umbilical cord mesenchymal stem cell injection in patients with Ankylosing Spondylitis, and to further explore the efficacy…
- Trial name
- NCT05962762
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells
- Volunteers
- 9 people
- Sponsor
- Asia Cell Therapeutics (Shanghai) Co., Ltd.
Ankylosing Spondylitis
Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis
The objective of this study was to evaluate the safety and efficacy of adalimumab 40 mg given every other week (eow) in subjects with active ankylosing spondylitis (AS) who have had an inadequate response to, or who are…
- Trial name
- ATLAS (NCT00085644)
- Testing
- adalimumab (D2E7)
- Where
- 22 sites in United States
- Volunteers
- 315 people
- Sponsor
- Abbott
Axial Spondyloarthritis
ToFAcitinib in Early Active Axial SpondyloarThritis:
This is a phase IV, multicentre, randomized, double-blind, placebo-controlled study designed to compare the efficacy and safety of tofacitinib versus placebo (on a background of an NSAID) over 16 weeks of treatment and 4 weeks of…
- Trial name
- FASTLANE (NCT06112665)
- Testing
- Tofacitinib 5 MG
- Where
- Germany
- Volunteers
- 104 people
- Sponsor
- Charite University, Berlin, Germany
Rheumatoid Arthritis, Inflammatory Bowel Disease
Incidence of Hospitalizations for Serious Infections in Patients Receiving Biologic Anti-Inflammatories for Rheumatologic, Psoriatic, and Gastrointestinal Conditions: A Descriptive Analysis
Purpose: With the existing biologic anti-inflammatory product patents expiring and the FDA approval of new biosimilar and innovator biologics, patients with rheumatologic (RA), psoriatic (PsO-PsA-AS), and gastrointestinal (GI)…
- Conditions
- Rheumatoid Arthritis, Inflammatory Bowel Disease, Psoriasis, Psoriatic Arthritis
- Trial name
- NCT02922192
- Testing
- TNF-α antagonists, non-TNFs, DMARD non-biologics
- Volunteers
- 90,360 people
- Sponsor
- Biologics & Biosimilars Collective Intelligence Consortium
Axial Spondyloarthritis
Effects of Nonsteroidal Anti-Inflammatory Drugs in Recurrence of Spondyloarthritis Patients After Remission
The multicenter, randomized controlled trial is to investigate and evaluate the effect of NSAIDs therapy on recurrence in patients with axial spondyloarthritis;
- Trial name
- NCT03425812
- Testing
- To withdraw NSAIDs therapy, To continue NSAIDs therapy
- Where
- China
- Volunteers
- 140 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Psoriatic Arthritis, Axial Spondyloarthritis
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.
- Trial name
- NCT07290036
- Testing
- Bimekizumab regimen 1 iv, Bimekizumab regimen 2 iv, Bimekizumab regimen 3 sc
- Where
- 63 sites in United States, Bulgaria and 4 more
- Volunteers
- 392 people
- Sponsor
- UCB Biopharma SRL
Ankylosing Spondylitis
Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis
The aim of the study is to investigate the efficacy and safety of adalimumab in combination with secukinumab for the treatment of ankylosing spondylitis.
- Trial name
- NCT06833112
- Testing
- Secukinumab, Adalimumab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Affiliated Hospital Of Guizhou Medical University
Spondylitis, Ankylosing
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
The purpose of the study is to evaluate the efficacy and tolerability of two doses of etoricoxib compared to naproxen in the treatment of ankylosing spondylitis (AS).
- Trial name
- NCT01208207
- Testing
- Part I - etoricoxib 60 mg, Part I - etoricoxib 90 mg, Part I- naproxen 1000 mg
- Volunteers
- 1,015 people
- Sponsor
- Organon and Co
Ankylosing Spondylitis
Patient Education in Ankylosing Spondylitis
This study was carried out to investigate the effect of a nurse-led disease management education program in AS on patient compliance, disease activity, functional capacity, kinesiophobia, and quality of life.
- Trial name
- NCT06185712
- Testing
- Nurse-led disease management education
- Where
- Turkey (Türkiye)
- Volunteers
- 122 people
- Sponsor
- Zeliha Tülek
Ankylosing Spondylitis, Muscle Weakness
Muscle Architecture in Ankylosing Spondylitis
The goal of this observational study is to determine whether there is a decrease in muscle mass and the relationship between lower extremity skeletal muscle mass, muscle strength and disease activity in Ankylosing spondylitis.
- Conditions
- Ankylosing Spondylitis, Muscle Weakness, Rheumatic Diseases
- Trial name
- NCT06226792
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Bezmialem Vakif University
Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Patients with active Axial Spondyloarthritis without x-ray evidence of Ankylosing Spondylitis and with signs of inflammation will be randomly assigned to receive certolizumab pegol (CZP) 200 mg every two weeks or placebo.
- Conditions
- Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA
- Trial name
- C-AXSPAND (NCT02552212)
- Testing
- Certolizumab Pegol
- Where
- 105 sites in United States, Australia and 7 more
- Volunteers
- 317 people
- Sponsor
- UCB BIOSCIENCES GmbH
Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA)
Biomarkers in Ankylosing Spondylitis
In this study, we aimed to compare serum PGRN(progranulin) and TNF-α levels in AS patients with healthy controls and to determine the relationship between TNF-α inhibitor use and PGRN levels in AS patients.
- Trial name
- NCT07117344
- Where
- Turkey (Türkiye)
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Kirsehir Ahi Evran Universitesi
Spondylitis, Ankylosing
16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
The purpose of this study was to generate 16-week efficacy data, as well as up to 3-year efficacy, safety and tolerability data in subjects with active AS despite current or previous NSAID, DMARD and/or anti-TNF therapy.
- Trial name
- MEASURE 3 (NCT02008916)
- Testing
- Secukinumab
- Where
- 57 sites in United States, Belgium and 8 more
- Volunteers
- 226 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis
Hematological Parameters in Axial Spondyloarthritis
Axial spondyloarthritis is an inflammatory disease characterized by the involvement of the sacroiliac joints and the spine. Disease activity and structural changes are determined by using physical examination, imaging studies…
- Trial name
- NCT05450133
- Testing
- Systemic inflammatory index, BASDAI, ASDAS-ESR
- Where
- Turkey (Türkiye)
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Bozyaka Training and Research Hospital
Central Sensitisation, Axial Spondyloarthritis
The Relationship Between Magnetic Resonance Imaging (MRI) Scores and Sensory Testing in Axial Spondyloarthritis
Axial spondyloarthritis is one of the most common rheumatic diseases and chronic pain and morning stiffness are the main complaints of these patients.
- Conditions
- Central Sensitisation, Axial Spondyloarthritis, Inflammation
- Trial name
- NCT05021783
- Testing
- Pressure pain threshold, Central Sensitization Inventory, Spondyloarthritis Research Consortium of Canada scoring system
- Where
- Turkey (Türkiye)
- Volunteers
- 24 people
- Sponsor
- Marmara University
Ankylosing Spondylitis, Therapeutic Agent Toxicity
A Randomized Open-labeled Study for Comparing Methods of Using Imrecoxib to Treat AS
The selective cox-2 inhibitor has been widely used in the treatment of Ankylosing spondylitis (AS). The Imrecoxib is a new cox-2 inhibitor. But the treatment strategy has not been decided yet.
- Trial name
- NCT04400786
- Testing
- intermittent treatment, continuous treatment
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Shanghai Zhongshan Hospital
Psoriatic Arthritis, Rheumatoid Arthritis
Activating the Cholinergic Anti-Inflammatory Pathway in Healthy Volunteers and People With Inflammatory Arthritis
This study is designed to investigate whether non-invasive ultrasound (US) that is optimized for stimulation and can elicit an anti-inflammatory response in people with Inflammatory Arthritis as compared to a sham intervention.
- Conditions
- Psoriatic Arthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- NCT06555562
- Testing
- Ultrasound Stimulation, Non-active ultrasound stimulation
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Surf Therapeutics
Axial Spondyloarthritis
Treat to Target Trial in Axial Spondylo Arthritis : The TICOSPA (Tight Control in Spondyloarthritis)
This is a not interventional, pragmatic, prospective, randomized (cluster) study to evaluate the potential benefit of a Treat to Target approach in comparison to routine treatment (i.e.
- Trial name
- TICOSPA (NCT03043846)
- Testing
- Follow-up every 3 months during 1 year (data collection in eCRF), Follow-up every month to follow the pre-defined strategy
- Where
- 18 sites in Belgium, France and 1 more
- Volunteers
- 163 people
- Sponsor
- Association de Recherche Clinique en Rhumatologie
Enthesitis Related Arthritis (ERA)
A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis
The purpose of this study is to evaluate the efficacy and safety of adalimumab given subcutaneously every other week (eow) as compared to placebo in pediatric subjects with Enthesitis Related Arthritis (ERA).
- Trial name
- NCT01166282
- Testing
- adalimumab
- Volunteers
- 46 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Spondyloarthritis (SpA), Ankylosing Spondylitis (AS)
Bidirectional Cohort Study of Nanfang Spondyloarthritis
Spondyloarthritis（SpA） patients attending Nanfang Hospital of Southern Medical University will generate a large number of clinical condition scales, laboratory indicators, imaging data such as X-rays or MRIs in the course of…
- Trial name
- BCNS (NCT06988813)
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Nanfang Hospital, Southern Medical University